1. Home
  2. VIGL vs DGHI Comparison

VIGL vs DGHI Comparison

Compare VIGL & DGHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • DGHI
  • Stock Information
  • Founded
  • VIGL 2020
  • DGHI 2017
  • Country
  • VIGL United States
  • DGHI United States
  • Employees
  • VIGL N/A
  • DGHI N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • DGHI Finance: Consumer Services
  • Sector
  • VIGL Health Care
  • DGHI Finance
  • Exchange
  • VIGL Nasdaq
  • DGHI Nasdaq
  • Market Cap
  • VIGL 89.3M
  • DGHI 90.1M
  • IPO Year
  • VIGL 2022
  • DGHI N/A
  • Fundamental
  • Price
  • VIGL $2.64
  • DGHI $2.99
  • Analyst Decision
  • VIGL Strong Buy
  • DGHI Strong Buy
  • Analyst Count
  • VIGL 5
  • DGHI 1
  • Target Price
  • VIGL $21.00
  • DGHI $2.50
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • DGHI 838.9K
  • Earning Date
  • VIGL 03-25-2025
  • DGHI 04-02-2025
  • Dividend Yield
  • VIGL N/A
  • DGHI N/A
  • EPS Growth
  • VIGL N/A
  • DGHI N/A
  • EPS
  • VIGL N/A
  • DGHI N/A
  • Revenue
  • VIGL N/A
  • DGHI $42,146,057.00
  • Revenue This Year
  • VIGL N/A
  • DGHI N/A
  • Revenue Next Year
  • VIGL N/A
  • DGHI N/A
  • P/E Ratio
  • VIGL N/A
  • DGHI N/A
  • Revenue Growth
  • VIGL N/A
  • DGHI 100.56
  • 52 Week Low
  • VIGL $1.49
  • DGHI $0.84
  • 52 Week High
  • VIGL $6.06
  • DGHI $3.77
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.47
  • DGHI 61.88
  • Support Level
  • VIGL $2.22
  • DGHI $2.81
  • Resistance Level
  • VIGL $2.53
  • DGHI $3.17
  • Average True Range (ATR)
  • VIGL 0.29
  • DGHI 0.49
  • MACD
  • VIGL 0.08
  • DGHI 0.02
  • Stochastic Oscillator
  • VIGL 80.47
  • DGHI 62.22

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About DGHI Digihost Technology Inc. Common Subordinate Voting Shares

Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.

Share on Social Networks: